ABVC BioPharma Q3 2026 Earnings Date & Estimates

ABVC BioPharma (NASDAQ:ABVC) is a clinical-stage biotechnology company developing pharmaceutical and diagnostic products. The company focuses primarily on therapies for central nervous system disorders, oncology and ophthalmic conditions, using a combination of internal research, licensing arrangements and collaborations with academic and industry partners.

ABVC’s development portfolio includes investigational treatments for conditions such as depression, attention-deficit/hyperactivity disorder, pancreatic cancer and certain eye diseases. Its programs are at various stages of preclinical and clinical development, and the company’s activities include advancing candidates through clinical trials, regulatory processes and potential commercialization.

Based in Fremont, California, ABVC has business and research connections in the United States and Taiwan. The company was previously known as American BriVision (Holding) Corp. before adopting the ABVC BioPharma name. As a development-stage biotechnology company, its products remain subject to clinical, regulatory and commercial risks before they can become broadly available.